Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions for treating skin thickening

A skin, skin area technology, applied in the direction of preparations for skin care, skin diseases, pharmaceutical formulations, etc., which can solve problems such as increased skin thickness and risk of other skin abnormalities or symptoms

Inactive Publication Date: 2016-05-11
GALDERMA RES & DEV SNC
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Inhibition of apoptosis, with concomitant proliferation of keratinocytes, considerably increases skin thickness and risk of other skin abnormalities or symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions for treating skin thickening
  • Compositions for treating skin thickening
  • Compositions for treating skin thickening

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Embodiment 1 water-soluble external preparation

[0086] This example describes water-soluble topical formulations that can be used in the present invention.

[0087] The first aqueous topical formulation comprises: Brimonidine tartrate (0.01%-5% w / w); Puriteg (0.005% w / w) (stabilized chlorine dioxide) as a preservative; and inactive ingredients: boric acid , calcium chloride, magnesium chloride, potassium chloride, pure water, sodium borate, sodium carboxymethylcellulose, sodium chloride; adjust the pH to 5.6-6.6 with hydrochloric acid and / or sodium hydroxide. Osmolality is in the range of 250-350 Osmol / kg.

[0088] The second aqueous topical formulation comprises: brimonidine tartrate (0.2%-2% w / w); benzalkonium chloride (0.005% w / w.) as a preservative; and inactive ingredients: boric acid, calcium chloride , magnesium chloride, potassium chloride, pure water, sodium borate, sodium carboxymethylcellulose, sodium chloride; adjust the pH to 5.6-6.6 with hydrochloric a...

Embodiment 2

[0089] Embodiment 2 cream or ointment external preparation

[0090] This example describes cream or ointment topical formulations that can be used in the present invention.

[0091] The first cream formulation for external use (hydrophilic ointment) is as described in Table 2.

[0092] Table 2

[0093]

[0094]

[0095] Note to the fit: To prepare the formulation, melt the stearyl alcohol and white petrolatum on a steam bath and heat to 75°C. The other components previously dissolved in water and heated to 75°C were added and the resulting mixture was stirred until solidified. The resulting mixture was then cooled and stirred before adding brimonidine tartrate as a concentrated solution.

[0096] Ointment external preparation (hydrophilic ointment) is as described in Table 3.

[0097] table 3

[0098] components

[0099] To prepare the formulation, stearyl alcohol and white wax are mixed together on a steam bath. Then add the cholesterol and stir until it...

Embodiment 3

[0100] Embodiment 3 gel preparation for external use

[0101] This example describes gel topical formulations that can be used in the present invention.

[0102] The first gel formulation is described in Table 4.

[0103] Table 4

[0104] components

weight%

Brimonidine tartrate

0.01–5%

Methylparaben NF

0.15%

Propylparaben NF

0.03%

Carboxyethyl cellulose NF

1.25%

Edetate Disodium USP

0.05%

Pure water, USP

Appropriate amount

total

100%

[0105] The second gel formulation is described in Table 5.

[0106] table 5

[0107] components

weight%

Brimonidine tartrate

0.5%

Methylparaben

0.20%

Propylparaben

0.05%

Carbomer 934P NF

1.0%

sodium hydroxide

Appropriate amount, pH 7

Pure water, USP

Appropriate amount

total

100%

[0108] All components were mixed to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Compositions and products for treating or reducing skin thickening in a subject are described. Also described are compositions for use in methods of inhibiting a skin disorder induced by an UV- irradiation. The methods involve topically administering to the subject a composition containing an adrenergic receptor agonist, such as brimonidine.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Patent Application No. 61 / 858,885, filed July 26, 2013, the disclosures of each of which are incorporated herein by reference. Background of the invention [0003] Abnormal cell proliferation results in thickening of the skin, which can be triggered by a variety of causes including (but not limited to): UV radiation. Epidermal growth factor receptor or EGFR (also known as ErbB1 and HER1) is a cell surface protein that is activated by binding to its specific ligands such as epidermal growth factor and transforming growth factor alpha (TGFα), etc. . Activation of EGFR leads to cell proliferation, inhibits cell death, and increases epidermal hyperplasia (ie, increases the number and size of normally arranged normal cells). When the skin is stimulated by UV radiation, EGFR increases keratinocyte proliferation, inhibits apoptosis, and increases and accelerates epidermal hyp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/498A61K31/4174A61K31/137A61K45/06A61Q19/00A61P17/00A61P35/00A61P17/12
CPCA61K45/06A61K31/137A61K31/4174A61K8/4946A61Q17/04A61Q19/004A61K31/498A61P17/00A61P17/12A61P17/16A61P35/00A61P43/00A61K8/494A61Q19/08
Inventor G·布维耶
Owner GALDERMA RES & DEV SNC